MA31683B1 - Composes et procedes pour moduler fxr - Google Patents

Composes et procedes pour moduler fxr

Info

Publication number
MA31683B1
MA31683B1 MA32615A MA32615A MA31683B1 MA 31683 B1 MA31683 B1 MA 31683B1 MA 32615 A MA32615 A MA 32615A MA 32615 A MA32615 A MA 32615A MA 31683 B1 MA31683 B1 MA 31683B1
Authority
MA
Morocco
Prior art keywords
methods
modulation components
fxr modulation
fxr
dyslipidemia
Prior art date
Application number
MA32615A
Other languages
Arabic (ar)
English (en)
Inventor
Michael James Genin
Francisco Javier Agejas-Chicharro
Melendo Ana Belen Bueno
Peter Rudolph Manninen
Alan M Warshawsky
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA31683B1 publication Critical patent/MA31683B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)

Abstract

L'invention concerne des composés de formule (i) dans laquelle les variables sont telles que définies ici et leurs compositions pharmaceutiques et des procédés d'utilisation, utiles pour traiter une dyslipidémie et des maladies liées à une dyslipidémie.
MA32615A 2007-07-16 2010-02-11 Composes et procedes pour moduler fxr MA31683B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94997407P 2007-07-16 2007-07-16
PCT/US2008/069719 WO2009012125A1 (fr) 2007-07-16 2008-07-11 Composés et procédés pour moduler le fxr

Publications (1)

Publication Number Publication Date
MA31683B1 true MA31683B1 (fr) 2010-09-01

Family

ID=39855171

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32615A MA31683B1 (fr) 2007-07-16 2010-02-11 Composes et procedes pour moduler fxr

Country Status (31)

Country Link
US (1) US8153624B2 (fr)
EP (1) EP2178851B1 (fr)
JP (1) JP5373788B2 (fr)
KR (1) KR101157334B1 (fr)
CN (1) CN101743232B (fr)
AR (1) AR067540A1 (fr)
AT (1) ATE539065T1 (fr)
AU (1) AU2008276236B2 (fr)
BR (1) BRPI0814571A2 (fr)
CA (1) CA2693406C (fr)
CL (1) CL2008002051A1 (fr)
CO (1) CO6270212A2 (fr)
CY (1) CY1112298T1 (fr)
DK (1) DK2178851T3 (fr)
DO (1) DOP2010000018A (fr)
EA (1) EA016475B1 (fr)
EC (1) ECSP109879A (fr)
ES (1) ES2376176T3 (fr)
HR (1) HRP20120048T1 (fr)
IL (1) IL202234A0 (fr)
MA (1) MA31683B1 (fr)
MX (1) MX2010000502A (fr)
PE (1) PE20090809A1 (fr)
PL (1) PL2178851T3 (fr)
PT (1) PT2178851E (fr)
RS (1) RS52216B (fr)
SI (1) SI2178851T1 (fr)
SV (1) SV2010003458A (fr)
TN (1) TN2010000028A1 (fr)
TW (1) TW200906823A (fr)
WO (1) WO2009012125A1 (fr)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289883A1 (fr) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Nouveaux composés modulant l'activité du recepteur FXR (NR1H4)
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
WO2012087520A1 (fr) * 2010-12-20 2012-06-28 Irm Llc Compositions et procédés de modulation des récepteurs farnésoïdes x
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
JP2014500319A (ja) * 2010-12-20 2014-01-09 アイアールエム・リミテッド・ライアビリティ・カンパニー ファルネソイドｘ受容体を調節するための組成物および方法
EP2545964A1 (fr) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Nouveaux composés se liant au fxr (nr1 h4) et modulant son activité
WO2013037482A1 (fr) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Agonistes du récepteur du farnésoïde x pour le traitement et la prévention du cancer
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ａｍｐｋを活性化させるインダゾール化合物
MX377523B (es) 2013-09-11 2025-03-10 Inst Nat Sante Rech Med Metodos y composiciones farmaceuticas para el tratamiento de la infeccion por el virus de la hepatitis b.
SG11201603026PA (en) 2013-11-05 2016-05-30 Novartis Ag Compositions and methods for modulating farnesoid x receptors
CN104045635A (zh) * 2014-06-23 2014-09-17 华东理工大学 3,4,5-三取代异恶唑类化合物及其用途
EP3006939A1 (fr) 2014-10-06 2016-04-13 Gilead Sciences, Inc. Glycoprotéine riche en histidine comme marqueur de l'activation du récepteur farnésoïde X hépatique
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
EP3034499A1 (fr) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Nouveaux composés de modulation (FXR NR1H4)
EP3034501A1 (fr) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy contenant des composés de modulation (FXR NR1H4)
ES2905872T3 (es) 2015-02-06 2022-04-12 Intercept Pharmaceuticals Inc Composiciones farmacéuticas para terapia combinada
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
RU2712099C2 (ru) 2015-03-31 2020-01-24 Энанта Фармасьютикалс, Инк. Производные желчных кислот в качестве агонистов fxr/tgr5 и способы их применения
CN107613986A (zh) 2015-04-07 2018-01-19 英特塞普特医药品公司 用于组合疗法的药物组合物
CN106946867B (zh) * 2016-01-06 2019-11-12 广州市恒诺康医药科技有限公司 Fxr受体调节剂及其制备方法和用途
CN107021958A (zh) * 2016-02-01 2017-08-08 山东轩竹医药科技有限公司 Fxr受体激动剂
MX2018011813A (es) 2016-03-28 2019-01-24 Intercept Pharmaceuticals Inc Medicina obtenida mediante la combinacion de agonista fxr y arb.
US10080741B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10080742B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10080743B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10144729B2 (en) 2016-05-18 2018-12-04 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
US10149835B2 (en) 2016-05-18 2018-12-11 Elmore Patent Law Group, P.C. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017201152A1 (fr) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Dérivés d'isoxazole utilisés comme agonistes de fxr et leurs procédés d'utilisation
NZ748641A (en) 2016-06-13 2020-04-24 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
CA2968836C (fr) 2016-06-13 2025-09-02 Gilead Sciences, Inc. Composes modulant fxr (nr1h4)
TW201808283A (zh) 2016-08-05 2018-03-16 廣東東陽光藥業有限公司 含氮三環化合物及其在藥物中的應用
WO2018039384A1 (fr) 2016-08-23 2018-03-01 Ardelyx, Inc. Composés d'isoxazolyl-carbonyloxy azabicyclo [3.2.1] octane en tant qu'activateurs de fxr
CN116854681B (zh) * 2016-08-23 2026-05-26 阿德利克斯股份有限公司 用于治疗代谢病状和病症的激素受体调节剂
JP6915050B2 (ja) * 2016-09-14 2021-08-04 ノバルティス アーゲー Ｆｘｒアゴニストの新規のレジーム
CA3039124A1 (fr) * 2016-10-04 2018-04-12 Enanta Pharmaceuticals, Inc. Analogues de l'isoxazole en tant qu'agonistes de fxr et leurs procedes d'utilisation
WO2018081285A1 (fr) 2016-10-26 2018-05-03 Enanta Pharmaceuticals, Inc. Dérivés d'isoxazole contenant de l'urée utilisés comme agonistes de fxr et leurs procédés d'utilisation
CN108017636A (zh) * 2016-11-04 2018-05-11 合帕吉恩治疗公司 作为fxr调节剂的含氮杂环化合物
CN108218852A (zh) * 2016-12-15 2018-06-29 宁波百纳西药业有限公司 一种螺环化合物、其制备方法、组合物及用途
ES2982801T3 (es) 2017-03-28 2024-10-17 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de las enfermedades hepáticas
JP2020515564A (ja) 2017-03-30 2020-05-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル エピソーマルウイルスの持続性及び発現を低下させるための方法及び医薬組成物
RU2741306C1 (ru) 2017-04-12 2021-01-25 Ил Дон Фармасьютикал Ко., Лтд. Производные изоксазола в качестве агонистов ядерных рецепторов и их применение
CN109265471B (zh) * 2017-06-30 2021-06-04 轩竹生物科技有限公司 Fxr受体激动剂
CN109320509B (zh) * 2017-07-31 2022-02-08 轩竹生物科技股份有限公司 Fxr受体激动剂
CN111655680B (zh) 2017-09-14 2024-03-05 阿德利克斯股份有限公司 用于治疗代谢突变和纤维化病状及病症的激素受体调节剂
US11168079B2 (en) 2017-11-01 2021-11-09 Bristol-Myers Squibb Company Alkene compounds as farnesoid x receptor modulators
US11286252B2 (en) 2017-11-01 2022-03-29 Bristol-Myers Squibb Company Alkene spirocyclic compounds as farnesoid X receptor modulators
KR102731925B1 (ko) 2017-11-01 2024-11-18 브리스톨-마이어스 스큅 컴퍼니 파르네소이드 x 수용체 조정제로서의 멀티시클릭 화합물
JP7212693B2 (ja) 2017-11-01 2023-01-25 ブリストル－マイヤーズ スクイブ カンパニー ファルネソイドｘ受容体モジュレーターとしての架橋二環化合物
CN111278821B (zh) 2017-11-01 2023-10-03 百时美施贵宝公司 作为法尼醇x受体调节剂的螺环化合物
US10689391B2 (en) 2017-12-12 2020-06-23 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
EP3730491B1 (fr) * 2017-12-22 2022-07-20 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Dérivé d'isoxazole, son procédé de préparation et son utilisation
CN110128432B (zh) 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
WO2019160813A1 (fr) 2018-02-14 2019-08-22 Enanta Pharmaceuticals, Inc. Dérivés d'isoxazole en tant qu'agonistes de fxr et leurs procédés d'utilisation
CN110452235B (zh) * 2018-05-08 2023-02-17 中国科学院上海药物研究所 一类含氟异噁唑类化合物及其制备方法、药物组合物和用途
EP3844156A4 (fr) * 2018-08-30 2022-06-08 Terns Pharmaceuticals, Inc. Traitement de troubles hépatiques
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
KR102692309B1 (ko) 2019-01-15 2024-08-07 길리애드 사이언시즈, 인코포레이티드 Fxr (nr1h4) 조정 화합물
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
AR118050A1 (es) 2019-02-15 2021-09-15 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
US12319676B2 (en) 2019-02-15 2025-06-03 Bristol-Myers Squibb Company Substituted amide compounds useful as farnesoid X receptor modulators
JP7449300B2 (ja) 2019-02-15 2024-03-13 ブリストル－マイヤーズ スクイブ カンパニー ファルネソイドｘ受容体モジュレータとして有用な置換アミド化合物
JP7465883B2 (ja) 2019-02-15 2024-04-11 ブリストル－マイヤーズ スクイブ カンパニー ファルネソイドｘ受容体モジュレータとしての置換二環式化合物
WO2020172075A1 (fr) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Formes solides d'agonistes de fxr
MX2021012750A (es) 2019-04-19 2021-11-18 Shanghai Inst Materia Medica Cas Agonista de molécula pequeña del fxr y método de preparación para el mismo y uso del mismo.
WO2020231917A1 (fr) * 2019-05-13 2020-11-19 Enanta Pharmaceuticals, Inc. Dérivés d'isoxazole utilisés en tant qu'agonistes de fxr et leurs procédés d'utilisation
US20220226350A1 (en) 2019-05-30 2022-07-21 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
WO2021009332A1 (fr) 2019-07-18 2021-01-21 Enyo Pharma Procédé pour diminuer les effets secondaires de l'interféron
CA3154488A1 (fr) 2019-08-23 2021-03-04 Terns Pharmaceuticals, Inc. Composes agonistes du recepteur beta de l'hormone thyroidienne
CA3154391A1 (fr) 2019-09-12 2021-03-18 Terns Pharmaceuticals, Inc. Composes agonistes du recepteur beta de l'hormone thyroidienne
KR20220098168A (ko) * 2019-11-08 2022-07-11 테른스 파마슈티칼스, 인크. 간 장애의 치료
WO2021108974A1 (fr) 2019-12-03 2021-06-10 Gannex Pharma Co., Ltd Composés pour moduler l'activité du fxr et leurs utilisations
IL293892A (en) 2020-01-15 2022-08-01 Inserm Institut National De La Sant? Et De La Rech M?Dicale Use of fxr agonists for treating an infection by hepatitis d virus
WO2021231646A1 (fr) * 2020-05-13 2021-11-18 Terns Pharmaceuticals, Inc. Polythérapie de troubles hépatiques
PE20231096A1 (es) 2020-08-25 2023-07-18 Lilly Co Eli Polimorfos de un inhibidor de ssao
EP4210705A4 (fr) * 2020-09-11 2024-11-13 Terns Pharmaceuticals, Inc. Formulations en dispersion solide d'un agoniste de fxr
CN114315830B (zh) 2020-09-30 2025-08-12 中国科学院上海药物研究所 Fxr小分子激动剂及其制备方法和用途
US20220135540A1 (en) * 2020-10-15 2022-05-05 Eli Lilly And Company Polymorphs of an fxr agonist
MX2023008365A (es) 2021-01-14 2023-10-04 Enyo Pharma Efecto sinérgico de un agonista de fxr e ifn para el tratamiento de infección por hbv.
TW202308629A (zh) 2021-04-28 2023-03-01 法商Ｅｎｙｏ製藥公司 使用fxr激動劑作為組合治療以增強tlr3激動劑之療效
AU2022387121A1 (en) 2021-11-11 2024-06-20 Terns Pharmaceuticals, Inc. Combination of a ssao inhibitor and thr-beta agonist for use in the treatment of liver disorders
WO2023220404A1 (fr) * 2022-05-13 2023-11-16 Terns Pharmaceuticals, Inc. Traitement de stéatohépatite non-alcoolique
CN115850152B (zh) * 2022-12-20 2025-10-31 河北鼎泰制药有限公司 一种杂质A-7-imp3的制备方法及其用途
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07138258A (ja) 1993-11-16 1995-05-30 Taiho Yakuhin Kogyo Kk チアゾリジンジオン誘導体又はその塩
ES2326850T3 (es) 1998-12-23 2009-10-20 Glaxo Group Limited Ensayos para ligandos de receptores nucleares.
US7105556B2 (en) 2001-05-30 2006-09-12 Bristol-Myers Squibb Company Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
US6967212B2 (en) * 2001-05-30 2005-11-22 Bristol-Myers Squibb Company Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
DE60131967D1 (de) 2001-08-13 2008-01-31 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
US6875782B2 (en) 2002-07-09 2005-04-05 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
JP2006515838A (ja) * 2002-11-22 2006-06-08 スミスクライン ビーチャム コーポレーション ファルネソイドｘ受容体アゴニスト
ES2452031T3 (es) 2006-02-03 2014-03-31 Eli Lilly & Company Compuestos y procedimientos para modular receptores FX
DK2029547T3 (da) * 2006-05-24 2010-07-26 Lilly Co Eli FXR-agonister
ES2340221T3 (es) 2006-05-24 2010-05-31 Eli Lilly And Company Compuestos y procedimientos para modular fxr.

Also Published As

Publication number Publication date
CY1112298T1 (el) 2015-12-09
PL2178851T3 (pl) 2012-05-31
MX2010000502A (es) 2010-03-26
CL2008002051A1 (es) 2009-05-29
AU2008276236B2 (en) 2013-03-14
TN2010000028A1 (en) 2011-09-26
CN101743232A (zh) 2010-06-16
EP2178851B1 (fr) 2011-12-28
SI2178851T1 (sl) 2012-02-29
AU2008276236A1 (en) 2009-01-22
PE20090809A1 (es) 2009-06-27
CA2693406C (fr) 2014-04-29
AR067540A1 (es) 2009-10-14
JP2010533722A (ja) 2010-10-28
PT2178851E (pt) 2012-02-27
CN101743232B (zh) 2013-03-06
DK2178851T3 (da) 2012-02-06
US8153624B2 (en) 2012-04-10
KR101157334B1 (ko) 2012-06-15
RS52216B (sr) 2012-10-31
HRP20120048T1 (hr) 2012-02-29
CO6270212A2 (es) 2011-04-20
IL202234A0 (en) 2010-06-16
SV2010003458A (es) 2011-01-10
KR20100020999A (ko) 2010-02-23
ECSP109879A (es) 2010-02-26
EP2178851A1 (fr) 2010-04-28
EA201070148A1 (ru) 2010-06-30
BRPI0814571A2 (pt) 2015-01-06
ATE539065T1 (de) 2012-01-15
EA016475B1 (ru) 2012-05-30
US20100152166A1 (en) 2010-06-17
CA2693406A1 (fr) 2009-01-22
DOP2010000018A (es) 2010-01-31
ES2376176T3 (es) 2012-03-09
TW200906823A (en) 2009-02-16
WO2009012125A1 (fr) 2009-01-22
JP5373788B2 (ja) 2013-12-18

Similar Documents

Publication Publication Date Title
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
WO2019035863A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques
MA64509B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA64121B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA32729B1 (fr) Derives d'acide 1-amino-2-cyclobutylethylboronique
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA30427B1 (fr) Derives bicycliques utilises comme inhibiteurs de cetp
MA34474B1 (fr) Agonistes de gpr40
MA29785B1 (fr) Agents permettant de prevenir et de traiter des troubles entrainant la modulation des recepteurs ryr
MA34767B1 (fr) Compositions et procédés pour la modulation de fxr
MA35036B1 (fr) Composés bis(fluoroalkyl)-1,4-benzodiazépinone
MA32134B1 (fr) Composés hétérocycliques
MA42410A (fr) Oxystérols et leurs méthodes d'utilisation
MA31952B1 (fr) Pyrrolopyrimidines et pyrrolopyridines
MA29568B1 (fr) Composes d'azaindazole et methodes d'utilisation desdits composes
MA38391A1 (fr) Dérivés de pyridinyl et triazolone pyridinyl de fusion
MA31419B1 (fr) Derives de pyridine
MA29909B1 (fr) Derives de pyridazine
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
MA31766B1 (fr) Composés organiques
MA31754B1 (fr) Cis-imidazolines chirales
MA29926B1 (fr) Derives de pyrazine
MA32466B1 (fr) Derives de triazole utiles pour le traitement de maladies
MA32150B1 (fr) Inhibiteurs heterocycliques de la stearoyl-coa desaturase